* patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (nsclc), (b) triple-negative breast cancer (tnbc; defined by estrogen receptor \[er\] \< 1%, progesterone receptor \[pr\] \< 1% and her2 1+ or less by immunohistochemistry \[ihc\]; if her-2 expression is 2+, a negative fluorescence in situ hybridization \[fish\] testing is required) (c) pancreatic adenocarcinoma (pdac), or (d) small cell lung cancer (sclc) * must have received at least one line of standard systemic treatment for locally advanced or metastatic disease setting of the respective tumor type; for nsclc, it is either pd-1/pd-l1 inhibitor, or platinum-containing chemotherapy, or an egfr tyrosine kinase inhibitor or an alk inhibitor if sensitizing mutation present; tnbc: platinum-containing chemotherapy; pdac: fluorouracil (5-fu-), gemcitabine-, or taxane-containing chemotherapy either with or without radiation therapy; sclc: platinum-containing chemotherapy for limited or extensive stage disease * patients must have measurable disease by response evaluation criteria in solid tumors (recist) version (v)1.1 * toxicities of prior therapy (except alopecia) should be resolved to =\< grade 1 as per national cancer institute (nci)-common terminology criteria for adverse events (ctcae) version (v)5.0; patients with long-standing stable grade 2 neuropathy or prior grade 2 treatment-related hypothyroidism requiring treatment, provided free t4 within normal range, may be considered eligible after discussion with the study principal investigator (pi) * eastern cooperative oncology group (ecog) performance status 0, 1 or 2 (karnofsky \>= 50%) * life expectancy of \>= 4 months * leukocytes \>= 3,000/mcl * absolute neutrophil count \>= 1,500/mcl * platelets \>= 100,000/mcl * hemoglobin \> 9 g/dl * total bilirubin =\< 1.5 x the institutional upper limit of normal (uln) * aspartate aminotransferase (ast) (serum glutamic oxaloacetic transaminase \[sgot\])/alanine aminotransferase (alt) (serum glutamate pyruvate transaminase \[sgpt\]) =\< 2.5 x institutional uln * creatinine =\< 1.5 x uln or * creatinine clearance \>= 45 ml/min/1.73 m\^2 for patients with creatinine levels above institutional normal; the creatinine clearance is calculated using cockcroft-gault formula * a urine protein: creatinine ratio of \< 1 or \< 1 g protein on 24-hour urine collection * international normalized ration (inr) within 1.25 x uln institutional limits, except where a lupus anti-coagulant has been confirmed * activated partial thromboplastin time (aptt) within 1.25 x uln institutional limits, except where a lupus anti-coagulant has been confirmed * patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib * adequately controlled thyroid function defined by free t4 within normal range, with no symptoms of thyroid dysfunction * adequately controlled blood pressure (bp) \< 140 mmhg (systolic) and \< 90 mmhg (diastolic) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of 3 antihypertensive medications; patients who are on 3 antihypertensive medications are highly recommended to be followed by a cardiologist or blood pressure specialist for management of bp while on protocol * patients who have the following risk factors are considered to be at increased risk for cardiac toxicities, and must have documented left ventricular ejection fraction (lvef) by echocardiogram greater than institution's lower limit of normal (or 55% if threshold for normal not otherwise specified by institutional guidelines) obtained within 3 months * prior treatment with anthracyclines * prior treatment with trastuzumab * a new york heart association (nyha) classification of ii controlled with treatment * prior central thoracic radiation therapy (rt), including rt to the heart * history of myocardial infarction within 12 months (patients with history of myocardial infarction within 6 months are excluded from the study) * the effects of cediranib and olaparib on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 4 months after completion of cediranib and olaparib administration * ability to understand and the willingness to sign a written informed consent document * age \>= 18 years. there is no dosing or adverse event data currently available on the use of cediranib or olaparib in patients \< 18 years of age, thus excluding them from enrollment

Breast Cancer > Boston, MA, USA

Sort: